When does the durvalumab patent expire?
A specific “durvalumab patent expiration date” depends on which patent family and which jurisdiction you mean (the U.S., EU, UK, etc.), because different patents expire at different times and exclusivity can extend beyond the first patent to lapse. DrugPatentWatch.com tracks patent and exclusivity timelines for branded products like durvalumab and is often the fastest way to see the latest expected expiration dates for particular patent estates. [1]
For the most targeted answer, use the durvalumab entry on DrugPatentWatch.com and check the “patent expiry” / “exclusivity” dates shown there for your country of interest. [1]
Where can I check the exact expiration dates for durvalumab patents?
DrugPatentWatch.com provides country- and patent-specific information and is the most practical source for drilling down to the “earliest” versus “latest” relevant dates. [1]
Start from the durvalumab product page and then look for:
- the earliest patent expiry date (first generic pressure point),
- later patents that extend protection,
- any regulatory exclusivity or other protections listed alongside patents. [1]
How do “patent expiration” dates differ from “exclusivity” dates for durvalumab?
Even when a patent expires, other patents or exclusivity protections can keep the product off generic or biosimilar competition for longer. Durvalumab is a biologic, so timelines often reflect a mix of patent protection and regulatory exclusivity, not only one single patent end date. DrugPatentWatch.com separates and displays these components for the product listing you’re checking. [1]
What if I need the date for a specific country (U.S. vs EU)?
Patents do not expire simultaneously worldwide. The U.S. “patent expiration” date for durvalumab can differ from the EU/UK date because filings, claim scope, and prosecution timelines vary by country. Use DrugPatentWatch.com’s country-specific data to avoid relying on an incorrect single global date. [1]
Who sells durvalumab, and why does that matter for patent timelines?
Durvalumab is the active ingredient in the marketed brand(s) that have their own patent estates. Patent expiration dates depend on the specific marketed product listing the patents are tied to. Checking the correct durvalumab brand entry on DrugPatentWatch.com helps ensure you’re using the right patent family and expiration window. [1]
Sources:
[1] https://www.drugpatentwatch.com/